Company intelligence / Profile preview

Theragen Bio Institute

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Theragen Bio is a leading South Korean precision medicine and genomics company that spun off from Theragen Etex in 2020. The company specializes in genome analysis, offering comprehensive services in clinical diagnostics, personal genetic testing, and bioinformatics. Beyond diagnostics, Theragen Bio is leveraging its deep genomic expertise to develop personalized cancer vaccines and targeted therapies through its proprietary neoantigen prediction platform. Their business model integrates high-throughput sequencing services with advanced R&D in oncology and drug discovery.

Therapeutic areas: Oncology
Modalities: VaccineSmall moleculeCell therapy
Industry: Biotech

Partnerships

Theragen EtexMedpacto

Beyond the preview

Go deeper on Theragen Bio Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragen Bio Institute.

Explore the full profile